Skip to main content
. 2015 Aug 22;6(31):32177–32192. doi: 10.18632/oncotarget.4867

Figure 5. GOLPH3 silencing inhibits the tumorigenicity of bladder cancer cells in vitro and in vivo.

Figure 5

A. The establishment of stable T24 bladder cancer cell lines expressing GOLPH3 and negative control shRNAs. The GFP expression ratio of T24 cells was greater than 90% 24 h post-cotransfection. B. GOLPH3 expression in stable T24 cells expressing GOLPH3 and negative control shRNAs was analyzed by western blot analysis. CCK8 assays C. indicated that the growth rates decreased in GOLPH3-silenced T24 cells. Flow cytometric analysis D. indicated that GOLPH3 stimulates the G1-S-phase transition of bladder cancer cells, and representative micrographs (left) and quantification (right) are shown. Stable knockdown of GOLPH3 by Lv-shRNA-GOLPH3 F. inhibits the growth of T24-derived xenografts in nude mice E. and G. Macrographic images show that the tumor size of the Lv-shRNA-GOLPH3 group was markedly smaller on the 40th day than those of the Lv-shRNA-NC group. The growth curves of the tumor xenografts and the final tumor weights of the Lv-shRNA-GOLPH3 group was decreased compared with those of the Lv-shRNA-NC group H. The tumor inhibition effect induced by GOLPH3 silencing in vivo correlate with the inhibition of AKT/mTOR signaling and Cyclin D1, MMP9 and increased p27 expression (F).